Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.41 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21875824 | 1.00 | ACE (0.45) | ACEMAPK1ITGB3ITGA2BITGA4 | |
| SCHEMBL20622191 | 0.89 | KLK5 (0.41) | ACEAKT1CTSSCTSLCTSB | |
| SCHEMBL28441375 | 0.89 | KLK5 (0.41) | ACEAKT1CTSSCTSLCTSB | |
| SCHEMBL16228847 | 0.80 | ACE (0.48) | ACEMAPK1ITGB3ITGA2BITGA4 | |
| SCHEMBL16119290 | 0.80 | ACE (0.48) | ACEMAPK1ITGB3ITGA2BITGA4 | |
| SCHEMBL14118068 | 0.75 | ACE (0.48) | ACEMAPK1ITGB3ITGA2BITGA4 | |
| SCHEMBL8131706 | 0.74 | ACE (0.46) | ACEPPARAPPARGKMT2AAKT1 | |
| SCHEMBL11349136 | 0.74 | ACE (0.47) | ACEMAPK1ITGB3ITGA2BITGA4 | |
| SCHEMBL15367523 | 0.74 | ACE (0.47) | ACEMAPK1ITGB3ITGA2BITGA4 | |
| SCHEMBL26980917 | 0.74 | ACE (0.47) | ACEMAPK1ITGB3ITGA2BITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3647315-B9 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | VIVAVISION BIOTECH LTD (CN) | 2025-06-04 | — | — | EP | disclosed |
| EP-3647315-B1 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | VIVAVISION BIOTECH LTD (CN) | 2024-11-20 | — | — | EP | disclosed |
| US-11325929-B2 | Phosphorus-containing compound and preparation and use thereof | VIVAVISIONSHANGHAILTD (CN) | 2022-05-10 | — | — | US | disclosed |
| EP-3647315-A1 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | Vivavisionshanghailtd (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-20200131206-A1 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | VIVAVISIONSHANGHAILTD (CN) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325929-B2 | Phosphorus-containing compound and preparation and use thereof | INPP5D, CXCL12, INPPL1 | ACE 1059/4885MAPK1 446/4885ITGB3 1739/4885 |
| US-20200131206-A1 | PHOSPHORUS-CONTAINING COMPOUND AND PREPARATION AND USE THEREOF | INPP5D, CXCL12, INPPL1 | ACE 1059/4885MAPK1 446/4885ITGB3 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.